SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (1080)6/28/1997 12:58:00 AM
From: I. Luttichuys   of 1762
 
That, I think, is our exact situation. The study has been halted due to problems with CD4 counts. The culprit will be either CE9.1 or placebo. More likely than not, it will be CE9.1. Historically and intuitively, it would make sense.
Now here is the question of the hour... is the problem something which can be corrected. The fact that Phase II wasn't halted for this problem suggests that, perhaps, there is hope that it is. That's where we are at... hoping that something in Phase III was different than in Phase II and that, whatever it is, it won't take much to correct.
If it were dosing, for example, that would be easier to deal with than some aspect of manufacture.
BENNETT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News